Developing nations neglecting healthcare sector, researchers say
A recent research, conduct in Canada, has revealed that people belonging to developing countries are at higher risk of succumbing […]
A recent research, conduct in Canada, has revealed that people belonging to developing countries are at higher risk of succumbing […]
World No Tobacco Day is celebrated worldwide on 31st May every year to encourage tobacco users to abstain from consumption of all forms of tobacco for a period of at least 24 hours.
Over one percent of all children born in India are born with congenital heart diseases.
The Mumbai-based firm has received approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) to market a generic version of Schering Plough’s Clarinex tablets, Sun Pharma said in a statement.
Drug maker Sun Pharma recently said it has received a tentative approval from US health regulator to sell a generic version of Crestor tablets, used in the treatment of various heart diseases, in the American market.
The Hon’ble Chief Minister Smt Sheila Dikshit pledged to support the Billion Hearts Beating (BHB) campaign launched by Apollo Hospitals Group.
Truworth brings state-of-the-art technology to India that is easy to implement anduse. The company offers products and services for the […]
Truworth brings state-of-the-art technology to India that is easy to implement and use. The company offers products and services for the entire list of stakeholders in the healthcare vertical.
[This article was published in the December 2009 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
Dr. SMS is a novel project of the Kerala State IT Mission – the technology implementation wing of the Government of Kerala in India, launched on 29th May 2008 with the aim to increase access of health care services by common people through simple and innovative use of mobile telephony.
In a move that would prevent MNCs such as GlaxoSmithKline (GSK), Eli Lilly, Roche and Pfizer from selling their drugs at a huge premium in India, the government may soon finalise norms for monitoring prices of costly imported patented medicines for diseases such as diabetes, arthritis, obesity, cancer and heart diseases.